On Tuesday, Ovid Therapeutics Inc (NASDAQ: OVID) opened lower -6.88% from the last session, before settling in for the closing price of $1.6. Price fluctuations for OVID have ranged from $0.24 to $2.01 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.72%. Company’s average yearly earnings per share was noted -23.59% at the time writing. With a float of $59.52 million, this company’s outstanding shares have now reached $71.11 million.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ovid Therapeutics Inc is 16.29%, while institutional ownership is 35.27%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.2 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.00% during the next five years compared to 24.72% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Check out the current performance indicators for Ovid Therapeutics Inc (OVID). In the past quarter, the stock posted a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 1.55 million, which is a jump from its year-to-date volume of 1.51 million. As of the previous 9 days, the stock’s Stochastic %D was 36.70%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 70.08%, which indicates a significant increase from 7.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1451 in the past 14 days, which was higher than the 0.1010 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3923, while its 200-day Moving Average is $0.6897. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.5867. Second resistance stands at $1.6833. The third major resistance level sits at $1.7367. If the price goes on to break the first support level at $1.4367, it is likely to go to the next support level at $1.3833. Now, if the price goes above the second support level, the third support stands at $1.2867.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
There are currently 71,110K shares outstanding in the company with a market cap of 105.95 million. Presently, the company’s annual sales total 570 K according to its annual income of -26,430 K. Last quarter, the company’s sales amounted to 6,270 K and its income totaled -4,680 K.
